Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Lancet
; 398(10295): 143-155, 2021 07 10.
Article
in En
| MEDLINE
| ID: mdl-34186022
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gastric Inhibitory Polypeptide
/
Double-Blind Method
/
Diabetes Mellitus, Type 2
/
Hypoglycemic Agents
Type of study:
Clinical_trials
Limits:
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
/
Asia
Language:
En
Journal:
Lancet
Year:
2021
Document type:
Article
Country of publication:
United kingdom